Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gemcitabine plus Erbitux in resected pancreatic cancer
2005-005168-94Phase 2Completed
- Sponsor
- Philipps-University of Marburg
- Start
- Jan 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, gemcitabine in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by Philipps-University of Marburg. Started Jan 2006; status: completed.
02
Drugs
cetuximabgemcitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2005-005168-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005168-94.